Cytogen (CYTO): Outcomes Data Demonstrating Prognostic Value of PROSTASCINT
Cytogen Corporation (NASDAQ: CYTO) reported the publication of data from a large cohort study demonstrating the value of PROSTASCINT in predicting outcomes for patients with prostate cancer.
The study evaluated patients whose PROSTASCINT images showed a localization pattern known as central abdomen uptake, a finding suggestive of metastatic disease, as compared to those without such findings. In the study, prostate cancer-specific death rates were 10 times higher in patients with CAU than in patients without CAU (p=0.005).
The study evaluated patients whose PROSTASCINT images showed a localization pattern known as central abdomen uptake, a finding suggestive of metastatic disease, as compared to those without such findings. In the study, prostate cancer-specific death rates were 10 times higher in patients with CAU than in patients without CAU (p=0.005).
You May Also Be Interested In
- Baxter Int'l (BAX) says low-glucose PD regimen has favorable impact on ESRD patients w/ diabetes
- Boehringer Ingelheim, Lilly (LLY) Say Linagliptin Showed Significant Improvement in HbA1c in Phase 3
- Sucampo Pharma (SCMP) Updates on Protective Effect of SPI-8811 in NSAID-Induced GMI
Create E-mail Alert Related Categories
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
